Biology of Renal Cell Carcinoma (Vascular Endothelial Growth Factor, Mammalian Target of Rapamycin, Immune Aspects)

摘要: The current approach of targeted therapies for renal cell carcinoma (RCC) is centralized on two pathways largely responsible the progression RCC. This chapter will explore biology RCC, effects disrupting conserved in advanced and a look into these main regulatory pathways. Clear pathophysiology characterized by loss tumor suppressor von Hippel–Lindau (VHL) gene subsequent disruption hypoxia-inducible factor (HIF) pathway. It regulation delicate balance proper induction protein expression that maintains normal physiological state kidney; this vascular endothelial growth (VEGF) mammalian target rapamycin (mTOR) as well what perturbations stemming from VHL or mutation can result Finally, we touch immunologic monitoring RCC opportunities related to manipulating immune system treating patients with